Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

Ursodeoxycholic Acid in the Prevention of Gallstone Formation After Bariatric Surgery: an Updated Systematic Review and Meta-analysis.

Magouliotis DE, Tasiopoulou VS, Svokos AA, Svokos KA, Chatedaki C, Sioka E, Zacharoulis D.

Obes Surg. 2017 Nov;27(11):3021-3030. doi: 10.1007/s11695-017-2924-y. Review.

PMID:
28889240
2.

Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence.

Bezzio C, Festa S, Saibeni S, Papi C.

Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):339-347. doi: 10.1080/17474124.2017.1292129. Epub 2017 Feb 16. Review.

PMID:
28165825
3.

Greater Adherence to Cancer Prevention Guidelines Is Associated with Higher Circulating Concentrations of Vitamin D Metabolites in a Cross-Sectional Analysis of Pooled Participants from 2 Chemoprevention Trials.

Kohler LN, Hibler EA, Harris RB, Oren E, Roe DJ, Jurutka PW, Jacobs ET.

J Nutr. 2017 Mar;147(3):421-429. doi: 10.3945/jn.116.243352. Epub 2017 Jan 25.

4.

Chemoprevention of colorectal cancer in inflammatory bowel disease.

Ehrlich AC, Patel S, Meillier A, Rothstein RD, Friedenberg FK.

Expert Rev Anticancer Ther. 2017 Mar;17(3):247-255. doi: 10.1080/14737140.2017.1283987. Epub 2017 Feb 1. Review.

PMID:
28095263
5.

The Peri-operative Bariatric Surgery Care in the Middle East Region.

Nimeri A, Al Hadad M, Khoursheed M, Maasher A, Al Qahtani A, Al Shaban T, Fawal H, Safadi B, Alderazi A, Abdalla E, Bashir A.

Obes Surg. 2017 Jun;27(6):1543-1547. doi: 10.1007/s11695-016-2503-7.

PMID:
28000089
6.

The Association of Ursodeoxycholic Acid Use With Colorectal Cancer Risk: A Nationwide Cohort Study.

Huang WK, Hsu HC, Liu JR, Yang TS, Chen JS, Chang JW, Lin YC, Yu KH, Kuo CF, See LC.

Medicine (Baltimore). 2016 Mar;95(11):e2980. doi: 10.1097/MD.0000000000002980.

7.

CANCERPREVENTIVE IN ULCERATIVE COLITIS.

Podolskaya DV, Shapina MV, Khalif IL.

Eksp Klin Gastroenterol. 2016;(8):4-8. Review. English, Russian.

PMID:
29874428
8.

Chemoprevention of esophageal adenocarcinoma in a rat model by ursodeoxycholic acid.

Ojima E, Fujimura T, Oyama K, Tsukada T, Kinoshita J, Miyashita T, Tajima H, Fushida S, Harada S, Mukaisho K, Hattori T, Ohta T.

Clin Exp Med. 2015 Aug;15(3):343-50. doi: 10.1007/s10238-014-0301-x. Epub 2014 Jul 18.

PMID:
25034655
9.

Protective efficacy of ursodeoxycholic acid nanoparticles in animal model of inflammatory bowel disease.

De AK, Sana S, Datta S, Mukherjee A.

J Microencapsul. 2014;31(8):725-37. doi: 10.3109/02652048.2014.918666. Epub 2014 Jun 25.

PMID:
24963957
10.

In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids.

Peng S, Huo X, Rezaei D, Zhang Q, Zhang X, Yu C, Asanuma K, Cheng E, Pham TH, Wang DH, Chen M, Souza RF, Spechler SJ.

Am J Physiol Gastrointest Liver Physiol. 2014 Jul 15;307(2):G129-39. doi: 10.1152/ajpgi.00085.2014. Epub 2014 May 22.

11.

Associations between vitamin D-binding protein isotypes, circulating 25(OH)D levels, and vitamin D metabolite uptake in colon cancer cells.

Hibler EA, Jacobs ET, Stone AD, Sardo CL, Galligan MA, Jurutka PW.

Cancer Prev Res (Phila). 2014 Apr;7(4):426-34. doi: 10.1158/1940-6207.CAPR-13-0269. Epub 2014 Jan 28.

12.

[Chemoprevention of colorectal cancer in inflammatory bowel disease].

Han SH, Lee J.

Korean J Gastroenterol. 2014 Jan 25;63(1):3-10. Review. Korean.

13.

Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls.

van Heumen BW, Roelofs HM, te Morsche RH, Nagengast FM, Peters WH.

Orphanet J Rare Dis. 2013 Nov 19;8:181. doi: 10.1186/1750-1172-8-181.

14.

Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I).

Sebastian S, Hernández V, Myrelid P, Kariv R, Tsianos E, Toruner M, Marti-Gallostra M, Spinelli A, van der Meulen-de Jong AE, Yuksel ES, Gasche C, Ardizzone S, Danese S.

J Crohns Colitis. 2014 Jan;8(1):5-18. doi: 10.1016/j.crohns.2013.04.008. Epub 2013 May 9. Review.

PMID:
23664897
15.

Differential proteomics identifies PDIA3 as a novel chemoprevention target in human colon cancer cells.

Ménoret A, Drew DA, Miyamoto S, Nakanishi M, Vella AT, Rosenberg DW.

Mol Carcinog. 2014 Feb;53 Suppl 1:E11-22. doi: 10.1002/mc.21986. Epub 2012 Dec 19.

PMID:
23255428
16.

Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons.

Carey EJ, Lindor KD.

Clin Res Hepatol Gastroenterol. 2012 Sep;36 Suppl 1:S61-4. doi: 10.1016/S2210-7401(12)70023-2.

PMID:
23141896
17.

Chemoprevention of colorectal cancer with ursodeoxycholic acid: pro.

Serfaty L.

Clin Res Hepatol Gastroenterol. 2012 Sep;36 Suppl 1:S53-60. doi: 10.1016/S2210-7401(12)70022-0.

PMID:
23141895
18.

Commentary: ursodeoxycholic acid as chemoprevention in inflammatory bowel disease and primary sclerosing cholangitis.

Santander C, Moreno-Otero R.

Aliment Pharmacol Ther. 2012 Apr;35(7):846; discussion 847. doi: 10.1111/j.1365-2036.2012.05019.x. No abstract available.

19.

Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells.

van Heumen BW, Roelofs HM, Te Morsche RH, Marian B, Nagengast FM, Peters WH.

Exp Cell Res. 2012 Apr 15;318(7):819-27. doi: 10.1016/j.yexcr.2012.02.004. Epub 2012 Feb 14.

PMID:
22366264
20.

Chemoprevention in familial adenomatous polyposis.

Kim B, Giardiello FM.

Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):607-22. doi: 10.1016/j.bpg.2011.08.002. Review.

Supplemental Content

Loading ...
Support Center